Altimmune Seeks Shareholder Approval to Double Authorized Stock, Potentially Enabling Significant Future Dilution

summarizeSummary

Altimmune has filed its definitive proxy statement, seeking shareholder approval to double its authorized common stock from 200 million to 400 million shares, a move that could lead to substantial future dilution.

check_boxKey Events · Corporate Governance and Compliance · ALT

• Shareholder Meeting Scheduled

  The Annual Meeting of Stockholders is scheduled for Thursday, April 16, 2026, at 8:30 a.m. Eastern Time, to be held virtually.

• Proposal to Double Authorized Common Stock

  The Board seeks approval to amend the Certificate of Incorporation, increasing authorized common stock from 200,000,000 to 400,000,000 shares. This follows the preliminary proxy statement filed on March 6, 2026, which first disclosed this intent.

• Significant Potential Dilution

  With 130,105,177 shares outstanding as of March 13, 2026, the additional 200,000,000 authorized shares represent a potential dilution of approximately 153.7% if fully issued.

• Increase in ESPP Share Reserve

  Shareholders will also vote on increasing the shares reserved under the 2019 Employee Stock Purchase Plan (ESPP) from 403,500 to 1,108,827 shares, an increase of 705,327 shares for employee incentives.

auto_awesomeAnalysis · ALT · Life Sciences

This definitive proxy statement outlines critical proposals for the upcoming annual meeting, most notably a request to double the authorized common stock from 200 million to 400 million shares. This move, previously signaled in a preliminary proxy, grants the board substantial flexibility for future capital raises, acquisitions, or other corporate transactions without requiring additional shareholder approval. If all these newly authorized shares were issued, it would represent a potential dilution of over 150% to current outstanding shares, a highly significant amount. While the company states this is for general corporate purposes and growth, such a large increase creates a considerable overhang and potential for future dilution. Additionally, the company seeks to increase shares for its Employee Stock Purchase Plan, a more modest dilutive measure aimed at employee retention. Investors should carefully consider the implications of this significant increase in authorized capital.